Ioannidis and Garber describe personalised cost-effectiveness for treatments

John Ioannidis and Alan Garber, both from Stanford, have just published a new and interesting article in PLoS Medicine on individualised cost-effectiveness analysis. They think (and I agree) that knowing that it costs $8.60 to get 20 extra days without the flu is worthwhile. Especially when another example says that people over 45 with knee … Continue reading Ioannidis and Garber describe personalised cost-effectiveness for treatments